TP53 and Miyoshi myopathy: Notably, alterations in the TP53 gene, including deletions and SNVs, are among the most well-studied genomic abnormalities in MM, frequently associated with poor prognosis, increased clonal fitness, and resistance to therapy [29,45,47].